NCT06889688 - Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | Biotech Hunter

Enrollment

246

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

September 20, 2030

Study Completion Date

March 31, 2031

Conditions

Breast Cancer Stage IV

Interventions

DRUG

Camrelizumab+Apatinib+Eribulin

Camrelizumab (200 mg, IV, Day 1) + Apatinib (250 mg, PO, QD) + Eribulin (1.4 mg/m², IV, Day 1 and Day 8) administered in 21-day cycles.

DRUG

Physician's choice chemotherapy

Physician's Choice Chemotherapy

Trial Locations (6)

Sun Yat-sen Memorial Hospital, Guangzhou

The Affiliated Hospital of Guizhou Medical University, Guiyang

Wuhan Union Hospital of China, Wuhan

Yichang Central People's Hospital, Yichang

Xiangya Hospital of Central South University, Changsha

The Central Hospital Of Yong Zhou, Yongzhou

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER